Alnylam Secures $2bn Financing From Blackstone By Monetizing Inclisiran Royalties
Alnylam successfully completed a multi-pronged financing deal with the investment firm, which it will use to fund the development of more RNAi drugs.
You may also be interested in...
The announcement that the Swiss giant is collaborating again with Alnylam could spark fresh speculation that the firms are moving closer to a merger – or not.
Novartis Pharmaceuticals US head Victor Bulto talks to Scrip about the launch of Leqvio; the cholesterol-lowering medicine now approved by the US FDA.
Blackstone is providing $250m to combine Intellia’s gene editing and Cellex’s cell manufacturing capabilities in a new CAR-T company using Cellex subsidiary GEMoaB’s technology and pipeline as a foundation.